Email this article Comparative Efficacies of Doxorubicin Complexes with Dextran Phosphate and Dextran Sulfate for Intracavity Chemotherapy of Zajdela Ascitic Hepatoma in Rats
- Authors: Minaeva O.V.1, Kokorev A.V.2, Petrov P.S.1, Kulikov O.A.1, Zaborovskii A.V.3, Gurevich K.G.3, Tararina L.A.3, Yunina D.V.3, Fedina A.M.3, Gromova E.V.1, Zharkov M.N.1, Brodovskaya E.P.1, Pyataev N.A.1
-
Affiliations:
- N. P. Ogarev Mordovia State University
- Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
- A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
- Issue: Vol 53, No 2 (2019)
- Pages: 125-128
- Section: Article
- URL: https://journals.rcsi.science/0091-150X/article/view/245633
- DOI: https://doi.org/10.1007/s11094-019-01965-6
- ID: 245633
Cite item
Open Access
Access granted
Subscription Access
Abstract
The efficacies of doxorubicin (Dox) complexes with carbohydrate polymers dextran phosphate (DP) and dextran sulfate (DS) in rats with grafted Zajdela ascitic hepatoma were studied in two series of experiments. The first studied the effects of the synthesized complexes on the cure rate and lifespan of the animals; the second, effects on ascites morphological parameters and Dox concentration in ascites fluid. The complexes were injected i.p. at a dose of 2 mg Dox/kg. The results showed that the Dox-DS complex reduced the lethality by 50% as compared with water-soluble Dox; the Dox-DP complex, by 28%. These complexes decreased statistically significantly the amount of ascites fluid and tumor-cell concentration in it. The drug was detected in ascites fluid 2 d after administration of Dox-DS and Dox-DP. The concentration of active ingredient in ascites fluid in animals treated with Dox-DS was >4 times higher than that in those treated with Dox-DP.
About the authors
O. V. Minaeva
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
A. V. Kokorev
Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
Email: azabor@mail.ru
Russian Federation, Obninsk, Kaluga Region, 249040
P. S. Petrov
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
O. A. Kulikov
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
A. V. Zaborovskii
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
Author for correspondence.
Email: azabor@mail.ru
Russian Federation, Moscow, 127473
K. G. Gurevich
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
Email: azabor@mail.ru
Russian Federation, Moscow, 127473
L. A. Tararina
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
Email: azabor@mail.ru
Russian Federation, Moscow, 127473
D. V. Yunina
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
Email: azabor@mail.ru
Russian Federation, Moscow, 127473
A. M. Fedina
A. I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the RF
Email: azabor@mail.ru
Russian Federation, Moscow, 127473
E. V. Gromova
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
M. N. Zharkov
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
E. P. Brodovskaya
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
N. A. Pyataev
N. P. Ogarev Mordovia State University
Email: azabor@mail.ru
Russian Federation, Saransk, Mordovia, 430005
